Azstarys (Serdexmethylphen/Dexmethylphen) Patent Expiration, LOE Window & CMS Spending

Azstarys (Serdexmethylphen/Dexmethylphen) by Commave Sub A Wholly Owned Sub Of Collegium: FDA Orange Book core substance LOE 2037-12-09, 0 AB generics, $73.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCommave Sub A Wholly Owned Sub Of Collegium
FDA Application & PathwayN212994 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-12-09
Last Listed Patent or Exclusivity Date2037-12-09
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$73.7M
2024 Medicare Part D Spend$2.1M
2024 Medicaid Spend$71.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel